scholarly journals The Inhibitory T Cell Receptors PD1 and 2B4 Are Differentially Regulated on CD4 and CD8 T Cells in a Mouse Model of Non-alcoholic Steatohepatitis

2019 ◽  
Vol 10 ◽  
Author(s):  
Cordula Hansel ◽  
Stephanie Erschfeld ◽  
Maike Baues ◽  
Twan Lammers ◽  
Ralf Weiskirchen ◽  
...  
Nature ◽  
2021 ◽  
Author(s):  
Justina X. Caushi ◽  
Jiajia Zhang ◽  
Zhicheng Ji ◽  
Ajay Vaghasia ◽  
Boyang Zhang ◽  
...  

AbstractPD-1 blockade unleashes CD8 T cells1, including those specific for mutation-associated neoantigens (MANA), but factors in the tumour microenvironment can inhibit these T cell responses. Single-cell transcriptomics have revealed global T cell dysfunction programs in tumour-infiltrating lymphocytes (TIL). However, the majority of TIL do not recognize tumour antigens2, and little is known about transcriptional programs of MANA-specific TIL. Here, we identify MANA-specific T cell clones using the MANA functional expansion of specific T cells assay3 in neoadjuvant anti-PD-1-treated non-small cell lung cancers (NSCLC). We use their T cell receptors as a ‘barcode’ to track and analyse their transcriptional programs in the tumour microenvironment using coupled single-cell RNA sequencing and T cell receptor sequencing. We find both MANA- and virus-specific clones in TIL, regardless of response, and MANA-, influenza- and Epstein–Barr virus-specific TIL each have unique transcriptional programs. Despite exposure to cognate antigen, MANA-specific TIL express an incompletely activated cytolytic program. MANA-specific CD8 T cells have hallmark transcriptional programs of tissue-resident memory (TRM) cells, but low levels of interleukin-7 receptor (IL-7R) and are functionally less responsive to interleukin-7 (IL-7) compared with influenza-specific TRM cells. Compared with those from responding tumours, MANA-specific clones from non-responding tumours express T cell receptors with markedly lower ligand-dependent signalling, are largely confined to HOBIThigh TRM subsets, and coordinately upregulate checkpoints, killer inhibitory receptors and inhibitors of T cell activation. These findings provide important insights for overcoming resistance to PD-1 blockade.


2014 ◽  
Vol 30 (S1) ◽  
pp. A18-A18
Author(s):  
Hongbing Yang ◽  
Sandrine Buisson ◽  
Giovanna Bossi ◽  
Gemma Hancock ◽  
Rebecca Ashfield ◽  
...  

1995 ◽  
Vol 756 (1 T-Cell Recept) ◽  
pp. 370-381 ◽  
Author(s):  
JENNIE C. C. CHANG ◽  
LAWRENCE R. SMITH ◽  
KAREN J. FRONING ◽  
BEVERLY J. SCHWABE ◽  
JULIE A. LAXER ◽  
...  

2015 ◽  
Vol 16 (9) ◽  
pp. 1323-1331 ◽  
Author(s):  
Sandra Höfflin ◽  
Sabrina Prommersberger ◽  
Ugur Uslu ◽  
Gerold Schuler ◽  
Christopher W Schmidt ◽  
...  

Cells ◽  
2020 ◽  
Vol 9 (5) ◽  
pp. 1264 ◽  
Author(s):  
Sebastian Klobuch ◽  
Kathrin Hammon ◽  
Sarah Vatter-Leising ◽  
Elisabeth Neidlinger ◽  
Michael Zwerger ◽  
...  

HLA-DPB1 antigens are mismatched in about 80% of allogeneic hematopoietic stem cell transplantations from HLA 10/10 matched unrelated donors and were shown to be associated with a decreased risk of leukemia relapse. We recently developed a reliable in vitro method to generate HLA-DPB1 mismatch-reactive CD4 T-cell clones from allogeneic donors. Here, we isolated HLA-DPB1 specific T cell receptors (TCR DP) and used them either as wild-type or genetically optimized receptors to analyze in detail the reactivity of transduced CD4 and CD8 T cells toward primary AML blasts. While both CD4 and CD8 T cells showed strong AML reactivity in vitro, only CD4 T cells were able to effectively eliminate leukemia blasts in AML engrafted NOD/SCID/IL2Rγc−/− (NSG) mice. Further analysis showed that optimized TCR DP and under some conditions wild-type TCR DP also mediated reactivity to non-hematopoietic cells like fibroblasts or tumor cell lines after HLA-DP upregulation. In conclusion, T cells engineered with selected allo-HLA-DPB1 specific TCRs might be powerful off-the-shelf reagents in allogeneic T-cell therapy of leukemia. However, because of frequent (common) cross-reactivity to non-hematopoietic cells with optimized TCR DP T cells, safety mechanisms are mandatory.


2011 ◽  
Vol 41 (8) ◽  
pp. 2414-2423 ◽  
Author(s):  
Caroline Scifo ◽  
Laura Mekaelian ◽  
Elisaphane Munyazesa ◽  
Anne-Marie Schmitt-Verhulst ◽  
Annick Guimezanes

Sign in / Sign up

Export Citation Format

Share Document